Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Stomach Neoplasms 10Carcinoma, Hepatocellular 10Carcinoma, Non-Small-Cell Lung 5Rectal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Recurrence 2Nasopharyngeal Carcinoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Squamous Non-Small Cell Lung Cancer SqNSCLC 1Spinocerebellar Degenerations 1Solid Tumor 1Small Cell Lung Carcinoma 1Resectable Non-small Cell Lung Cancer 1Rare Tumour 1Pancreatic Neoplasms 1Pancreatic Cancer Resectable 1Pancreatic Cancer Metastatic 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Locally Advanced Non-Small Cell Lung Cancer 1Hodgkin Disease 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1Esophageal Neoplasms 1

Interventions

Fluorodeoxyglucose F18 2toripalimab 1spartalizumab 1sintilimab 1osimertinib 1olaparib 1apatinib 1Ink 1Histocompatibility Testing 1Carboplatin 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Solid Tumor × sintilimab × Clear all
NCT07612137 2026-05-28

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2 Not yet recruiting
282 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡